Respiratory surveillance report

The Public Health Agency (PHA) has integrated influenza, respiratory syncytial virus (RSV) and COVID-19 reporting into this report to provide a single overview of the epidemiology of these infections in Northern Ireland (NI), along with the number of respiratory care home outbreaks, hospital admissions and occupancy, and deaths. It offers references to additional sources of information for further details.

1 Summary

In week 07, influenza and COVID-19 activity remain stable across the majority of surveillance indicators. Respiratory syncytial virus (RSV) activity continued to decrease across the majority of surveillance indicators.

  • There were 183 unique episodes of influenza identified (eight Flu A (H1), 22 Flu A (H3), 48 Flu A (not subtyped) and 105 Flu B). For RSV, there were 18 unique episodes identified and for COVID-19 there were 28 unique episodes identified.

  • There were 1,659 total influenza tests (11.3% positivity) and 941 total RSV tests (1.9% positivity) performed. For COVID-19, there were 1,619 tests performed (2.2% positivity).

  • The GP influenza/flu-like-illness (flu/FLI) consultation rate was 10.0 per 100,000 population. The GP acute respiratory infection (ARI) consultation rate was 121.7 per 100,000 population.

  • There was one RSV and one COVID-19 outbreak reported in care home settings to The Public Health Agency (PHA) Health Protection acute response duty room.

  • Of the 83 new admissions, 27 were Flu A, 33 were Flu B, 10 were RSV and 13 were COVID-19.

  • Community acquired emergency flu A and RSV inpatients decreased, while flu B inpatients have remained stable. COVID-19 inpatients have increased slightly.

 

2 Virology surveillance

2.1 Episodes of influenza, RSV and COVID-19

The number of new influenza episodes remained stable in week 07, with 183 unique episodes identified. There were 184 episodes reported in week 06. The number of new RSV episodes decreased in week 07, with 18 unique episodes identified. There were 26 episodes reported in week 06 (Figure 2.1).

Influenza and RSV episode rates by age groups are shown in (Figure 2.2). The highest influenza episode rate in week 07 was in the 0-4 age group (31.0 per 100,000 population). The highest RSV episode rate was in the 0-4 age group (6.2 per 100,000 population).

Influenza rates across local government districts (LGD) are shown in (Figure 2.3). Armagh City, Banbridge and Craigavon had the highest influenza rate in week 07 (14.1 per 100,000 population). The highest RSV rate was in Belfast (2.0 per 100,000 population).

The number of new COVID-19 episodes decreased in week 07, with 28 unique episodes identified compared to 30 in week 06 (Figure 2.1).

COVID-19 episode rates by age groups are shown in (Figure 2.2). The highest COVID-19 episode rate in week 07 was in the 75+ age group (9.2 per 100,000 population).

COVID-19 episode rates across LGD are shown in (Figure 2.3). Newry, Mourne and Down had the highest COVID-19 episode rate in week 07 (4.4 per 100,000 population).

Supplementary tables of key figures are shown at the end of this bulletin.

 

Weekly number of unique episodes of influenza, RSV and COVID-19 by epidemiological week

Figure 2.1: Weekly number of unique episodes of influenza, RSV and COVID-19 by epidemiological week

 

Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by age group, by epidemiological week

Figure 2.2: Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by age group, by epidemiological week

 

Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by local government district, by epidemiological week

Figure 2.3: Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by local government district, by epidemiological week

 

2.2 Testing and positivity (%)

In week 07 there were 1,659 total influenza tests, 188 of which were positive (11.3% positivity). This is similar to week 06 (10.7% positivity) (Figure 2.4).

There were 941 total RSV tests, 18 of which were positive (1.9% positivity). This is a decrease from week 06 (2.7% positivity) (Figure 2.4).

There were 1,619 COVID-19 tests, 35 of which were positive (2.2% positivity). This is similar to week 06 (1.8% positivity) (Figure 2.4).

Supplementary tables of key figures are shown at the end of this bulletin.

 

Weekly positivity for influenza, RSV and COVID-19, by epidemiological week

Figure 2.4: Weekly positivity for influenza, RSV and COVID-19, by epidemiological week

 

2.3 Influenza subtyping

Of the 183 new influenza episodes identified in week 07, eight were typed as Flu A (H1), 22 were Flu A (H3), 48 were Flu A (not subtyped) and 105 were Flu B (Figure 2.5).

 

Weekly number of unique episodes of influenza, by subtype and epidemiological week

Figure 2.5: Weekly number of unique episodes of influenza, by subtype and epidemiological week

 

2.4 Sentinel surveillance

Sentinel surveillance plays a role in monitoring and understanding the spread and impact of respiratory viruses like influenza and COVID-19 in the community. It involves a systematic and targeted approach to collect data from a geographical representative subset of GP practices (~18% population representative) to provide information about virus activity across NI.

In week 07, 5 samples were positive for influenza from 19 samples submitted for testing (26.3% positivity) to the Regional Virus Laboratory (RVL). One was typed as Flu A (H1), one was Flu A (H3), and three were Flu B. No samples were positive for RSV from 19 samples submitted for testing. No samples were positive for COVID-19 from 19 samples submitted for testing (Table 1).

Total sentinel cases of influenza, RSV and COVID-19 by age group for the previous year are shown in (Figure 2.6), (Figure 2.7) and (Figure 2.8), and cumulatively for the 2024/25 influenza season in Table 2.

Supplementary tables of key figures are shown at the end of this bulletin.

 

Table 1. Total sentinel tests and positivity for Influenza, RSV and COVID-19, current week

 

 

Total Tests

Total Positives

Positivity (%)

2025 - 07

Influenza

19

5

26.32

2025 - 07

RSV

19

0

0.00

2025 - 07

COVID-19

19

0

0.00

 

Weekly sentinel influenza cases, by age group, by epidemiological week

Figure 2.6: Weekly sentinel influenza cases, by age group, by epidemiological week

 

Weekly sentinel RSV cases, by age group, by epidemiological week

Figure 2.7: Weekly sentinel RSV cases, by age group, by epidemiological week

 

Weekly sentinel COVID-19 cases, by age group, by epidemiological week

Figure 2.8: Weekly sentinel COVID-19 cases, by age group, by epidemiological week

 

Table 2. Total sentinel cases of Influenza, RSV and COVID-19 by age group, Week 40 - current week, 2024/25

 

0-4

5-14

15-44

45-64

65-74

75+

Total

Flu A (H1)

27

22

94

58

22

23

246

Flu A (H3)

2

2

8

5

2

1

20

Flu A (not subtyped)

5

1

20

12

1

5

44

Flu B

3

6

55

8

1

1

74

RSV

18

4

13

13

7

9

64

COVID-19

0

0

4

2

3

9

18

 

2.5 Non-sentinel surveillance

Non-sentinel surveillance is the monitoring of respiratory viruses from virology data collected from settings such as hospitals and GPs (excluding the sentinel GPs). This provides information about virus activity across NI.

In week 07, 183 samples were positive for influenza from 1,640 samples submitted for testing to laboratories across NI (11.2% positivity). Eight were typed as Flu A (H1), 22 were Flu A (H3), 49 were Flu A (not subtyped), and 104 were Flu B. 18 samples were positive for RSV from 922 samples submitted for testing (2.0% positivity). 35 samples were positive for COVID-19 from 1,623 samples submitted for testing (2.2% positivity) (Table 3).

Total non-sentinel cases of influenza, RSV and COVID-19 by age group for the previous year are shown in (Figure 2.6), (Figure 2.7) and (Figure 2.11), and cumulatively for the 2024/25 influenza season in Table 4.

Supplementary tables of key figures are shown at the end of this bulletin.

 

Table 3. Total non-sentinel tests and positivity for Influenza, RSV and COVID-19, current week

 

 

Total Tests

Total Positives

Positivity (%)

2025 - 07

Influenza

1,640

183

11.16

2025 - 07

RSV

922

18

1.95

2025 - 07

COVID-19

1,623

35

2.16

 

Weekly non-sentinel influenza cases, by age group, by epidemiological week

Figure 2.9: Weekly non-sentinel influenza cases, by age group, by epidemiological week

 

Weekly non-sentinel RSV cases, by age group, by epidemiological week

Figure 2.10: Weekly non-sentinel RSV cases, by age group, by epidemiological week

 

Weekly non-sentinel COVID-19 cases, by age group, by epidemiological week

Figure 2.11: Weekly non-sentinel COVID-19 cases, by age group, by epidemiological week

 

Table 4. Total non-sentinel cases of Influenza, RSV and COVID-19 by age group, Week 40 - current week, 2024/25

 

0-4

5-14

15-44

45-64

65-74

75+

Total

Flu A (H1)

414

153

259

383

272

727

2,208

Flu A (H3)

37

24

45

45

14

42

207

Flu A (not subtyped)

732

373

502

527

316

725

3,175

Flu B

151

128

309

38

13

23

662

RSV

1,300

34

61

99

117

257

1,868

COVID-19

101

31

116

210

268

662

1,388

 

2.6 SARS-CoV-2 variants

XEC is a recombinant lineage of KS.1.1 and KP.3.3 (both of which are JN.1 sub-lineages). The KP.3 and other KP lineages are descended from JN.1 sub-lineages, and they are now reported separately from JN.1 to illustrate the evolving genomic epidemiology. For the week commencing 23rd December 2024, XEC accounted for 50.0% of all sequenced samples, KP.3 for 38.9%, and for JN.1 and KP both 5.6%, respectively. Due to small numbers of samples sequenced, the level of confidence in precision of the estimate is low, and the percentages of each variant may change as further results become available. A more detailed COVID-19 Genomics Bulletin containing a further breakdown of sub-lineages is published weekly. Technical information is published by UKSHA on some specific KP variants online.

Parent lineages displayed are subject to change based on lineages under monitoring by the UKHSA horizon scanning team.

 

Total number of sequenced variants of COVID-19 by Pangolin lineage, by epidemiological week

Figure 2.12: Total number of sequenced variants of COVID-19 by Pangolin lineage, by epidemiological week

Recombinant refers to any recombinant lineage, starting “X”, that does not fall under the parent lineage of a defined variant.

 

3 Primary care surveillance

3.1 Consultation rates for influenza/influenza-like-illness (‘flu/FLI’)

The general practice (GP) flu/FLI consultation rate during week 07 was 10.0 per 100,000 population. This is a decrease from week 06 (12.8 per 100,000 population). Rates are at baseline activity (<10.1 per 100,000 population) (Figure 3.1).

Flu/FLI consultation rates by age groups are shown in Table 5. The highest rate in week 07 was seen in the 15-44 age group (12.6 per 100,000 population).

Flu/FLI consultation rates by Health and Social Care Trust (HSCT) are shown in Table 6. The highest rate in week 07 was seen in the Southern Trust (13.1 per 100,000 population).

Since the beginning of the COVID-19 pandemic, the offer of uptake of GP consultations has changed. As a result, consultation rates in the most recent period are unlikely to be directly comparable to pre-pandemic and pandemic years.

 

Northern Ireland GP consultation rates for ‘flu/FLI’ 2021/22 – 2024/25

Figure 3.1: Northern Ireland GP consultation rates for ‘flu/FLI’ 2021/22 – 2024/25

The baseline MEM threshold for Northern Ireland is <10.1 per 100,000 population for 2024-25. Low activity is 10.1 to <20.5, moderate activity 20.5 to <47.4, high activity 47.4 to <68.5 and very high activity is >68.5 per 100,000 population.

 

Table 5. Flu/FLI consultation rates per 100,000 population, by age groups, over a six week period

 

0-4

5-14

15-44

45-64

65-74

75+

Total

2025 - 02

27.43

9.45

34.63

36.96

36.62

47.40

32.94

2025 - 03

23.63

13.23

26.18

36.41

27.97

42.14

28.54

2025 - 04

14.19

11.35

19.42

15.47

10.17

26.34

16.82

2025 - 05

20.81

8.32

17.85

11.83

10.67

16.38

14.46

2025 - 06

11.31

5.27

15.12

11.77

10.11

20.40

12.79

2025 - 07

7.53

3.38

12.57

11.21

6.55

9.31

9.99

 

Table 6. Flu/FLI consultation rates per 100,000 population, by Health and Social Care Trust, over a six week period

 

Belfast

Northern

Western

Southern

South Eastern

Northern Ireland

2025 - 02

25.05

24.60

48.30

38.54

33.67

32.94

2025 - 03

21.75

21.35

42.51

28.73

33.94

28.54

2025 - 04

18.90

11.25

23.42

17.75

14.90

16.82

2025 - 05

11.20

14.49

17.34

17.98

11.58

14.46

2025 - 06

8.17

10.29

17.63

16.11

13.79

12.79

2025 - 07

7.24

8.77

11.27

13.07

10.48

9.99

 

3.2 Consultation rates for acute respiratory infection (ARI)

The GP ARI consultation rate during week 07 was 121.7 per 100,000 population. This is a decrease from week 06 (131.0 per 100,000 population) (Figure 3.2).

ARI consultation rates by age groups are shown in Table 7. The highest rate in week 07 was seen in the 0-4 age group (516.0 per 100,000 population).

ARI consultation rates by HSCT are shown in Table 8. The highest rate in week 07 was seen in the Western Trust (137.9 per 100,000 population).

 

Northern Ireland GP consultation rates for ARI 2021/22 – 2024/25

Figure 3.2: Northern Ireland GP consultation rates for ARI 2021/22 – 2024/25

 

Table 7. ARI consultation rates per 100,000 population, by age groups, over a six week period

 

0-4

5-14

15-44

45-64

65-74

75+

Total

2025 - 02

375.51

69.18

112.10

155.84

186.13

224.13

147.18

2025 - 03

402.69

121.37

93.61

130.53

160.68

204.25

137.28

2025 - 04

403.02

117.61

78.04

92.29

115.37

127.58

110.39

2025 - 05

477.73

147.52

95.75

97.18

122.92

152.12

128.74

2025 - 06

498.48

164.53

91.53

97.99

131.45

148.65

130.95

2025 - 07

515.97

107.49

83.45

101.40

135.61

135.54

121.72

 

Table 8. ARI consultation rates per 100,000 population, by Health and Social Care Trust, over a six week period

 

Belfast

Northern

Western

Southern

South Eastern

Northern Ireland

2025 - 02

153.59

138.26

157.91

127.52

165.02

147.18

2025 - 03

131.61

137.47

160.20

119.34

143.47

137.28

2025 - 04

113.39

110.19

128.11

89.19

115.03

110.39

2025 - 05

125.45

133.04

154.36

98.52

137.90

128.74

2025 - 06

128.13

131.90

143.67

115.80

138.97

130.95

2025 - 07

126.33

118.36

137.89

100.61

130.15

121.72

 

4 Community surveillance

4.1 Influenza, RSV and COVID-19 care homes outbreaks

There was one RSV and one COVID-19 outbreak reported in care home settings in week 07. This is the same as week 06 (one RSV and one COVID-19 outbreak) (Figure 4.1).

 

Weekly number of confirmed influenza, RSV and COVID-19 outbreaks, by year and epidemiological week

Figure 4.1: Weekly number of confirmed influenza, RSV and COVID-19 outbreaks, by year and epidemiological week

 

5 Secondary care surveillance

5.1 Admissions and occupancy

There were 83 new community-acquired emergency hospital admissions during week 07 (Figure 5.1). This is an increase from week 06 (n=74). Of the 83 new admissions, 27 were Flu A, 33 were Flu B, 10 were RSV and 13 were COVID-19. The 15-44 age group had the majority of community acquired emergency influenza hospital admissions in week 07 (35.0%). The 0-4 age group had the majority of RSV hospital admissions (50.0%), and the 75+ age group had the majority of COVID-19 hospital admissions (46.2%).

Community acquired emergency flu A and RSV inpatients decreased, while flu B inpatients have remained stable. COVID-19 inpatients have increased slightly (Figure 5.2).

 

Weekly number of community-acquired emergency influenza, RSV and COVID-19 hospital admissions, by year and epidemiological week

Figure 5.1: Weekly number of community-acquired emergency influenza, RSV and COVID-19 hospital admissions, by year and epidemiological week

 

Influenza, RSV and COVID-19 community acquired emergency inpatients, by day

Figure 5.2: Influenza, RSV and COVID-19 community acquired emergency inpatients, by day

 

6 Mortality surveillance

6.3 Excess Mortality

NISRA use the UK-wide methodology to report on excess deaths as advised by the Office for National Statistics (ONS).

EuroMOMO is a European mortality monitoring activity, aiming to detect and measure excess deaths related to seasonal influenza, pandemics and other public health threats. Reports on excess deaths across Europe and the United Kingdom are published weekly.

 

7 Methods

7.1 Presentation of data

Unless otherwise stated, data are presented using epidemiological weeks (a standardised method of counting weeks [Monday-Sunday] to allow for the comparison of data year after year). This is dependent on the data available. The data included in this report are the most up to date data available at the time of the report; however, this is subject to change as the data are subject to ongoing quality assurance.

7.2 Virology surveillance

All virology data provided here are preliminary. Virology data for prior weeks, as included in this or future bulletins, are subject to updates based on laboratory returns received after the last report was produced. The current bulletin offers the most current information available.

Rates per 100,000 population are calculated using the NISRA 2021 Mid-Year Population Estimates.

7.2.1 Episodes of infection

Influenza

Influenza episodes are defined by a 42-day (6-week) period from the date of the first positive test result (utilising any test method, including PCR and Point of Care Tests, or source of sample, including hospital, GP, other source), with the episode beginning with the earliest positive specimen date. Subsequent positive specimen dates for the same individual within 42 days of the last are included in the one episode. Positive specimens for the same individual more than 42 days after the last are counted in a separate episode.

RSV

RSV episodes are defined by a 14-day (2-week) period from the date of the first positive test result (utilising any test method, including PCR and Point of Care Tests, or source of sample, including hospital, GP, other source), with the episode beginning with the earliest positive specimen date. Subsequent positive specimen dates for the same individual within 14 days of the last are included in the one episode. Positive specimens for the same individual more than 14 days after the last are counted in a separate episode.

COVID-19

COVID-19 episodes are defined by a rolling 90-day period between positive test results (any test method, sourced from the NI COVID-19 combined testing register), with the episode beginning with the earliest positive specimen date. Subsequent positive specimen dates for the same individual within 90 days of the last are included in the one episode. Positive specimens for the same individual more than 90 days after the last are counted in a separate episode.

7.2.2 Testing and positivity (%)

7.2.2.1 Influenza, RSV and COVID-19

Instead of utilising an episode-based approach, the data is analysed on an epidemiological week basis. Within each epidemiological week, an individual is limited to one influenza test, whether positive or negative. If an individual tests positive for influenza during a specific epidemiological week and subsequently tests positive again within the same week, the second positive test is not counted. Regardless of whether it occurs before or after a negative test within the same epidemiological week, a positive test always takes precedence and is recorded. Similarly, only the first test of multiple negative results is counted for each individual within any given epidemiological week. This helps prevent the double-counting of tests, particularly for individuals who may be hospitalised and routinely tested.

The same methodology is applied when analysing RSV and COVID-19 data.

7.2.2.2 Sentinel surveillance

The Public Health Agency works with GPs to deliver a community-based surveillance programme for respiratory infections in NI. The programme provides valuable intelligence about the circulation of respiratory viruses in NI to inform health and social care system planning and preparedness. Participation involves taking nasal/throat swabs from some symptomatic patients who agree to have a swab, and who attend (in person) with ILI, ARI or suspected COVID-19. Testing is opportunistic and within 10 days of symptom onset. Swabs are tested for influenza, RSV and COVID-19 at the RVL and surveillance is year-round.

7.2.2.3 SARS-CoV-2 genomics

A subset of SARS-CoV-2 positive PCR samples are sent to sequencing laboratories in Belfast Health and Social Care Trust and Queen’s University Belfast for sequencing. On 29th November the lineage assignment algorithm was switched from PangoLEARN to UShER for lineage counts. PangoLEARN uses a machine learning algorithm, whereas UShER uses phylogenetic placement and produces fewer unassigned lineages. This switch has been applied retrospectively, therefore total counts for all lineages have been affected. A more detailed COVID-19 Genomics Bulletin containing a further breakdown of sub-lineages is published weekly.

7.3 Primary care surveillance

7.3.1 Consultation rates for influenza/influenza-like-illness (‘flu/FLI’) and acute respiratory infection (ARI)

GP in-hours consultation data with ~95% coverage of the NI population is auto-extracted weekly from GPIP. This data includes weekly aggregate consultations for ‘flu/FLI’ and ARI, and includes weekly registered patients. The data is available for different Health and Social Care Trusts, and by age and sex.

7.4 Community surveillance

7.4.1 Care home outbreaks

PHA conducts surveillance of outbreaks across multiple settings, including care homes (nursing homes and residential homes) in NI that are registered with the Regulation and Quality Improvement Agency. All care homes have a requirement to notify the PHA Health Protection duty room of suspected outbreaks of any infectious disease. A confirmed outbreak of influenza or RSV can be defined as where there are two or more confirmed cases with onset within a 14 day period, where transmission within the Care Home facility is considered the likely cause.

7.5 Secondary care surveillance

7.5.1 Admissions and occupancy

Where it is currently possible (SHSCT and WHSCT) only admissions where the method of admission was ‘Emergency’ are counted. It is not currently possible for this report to distinguish emergency from other types of admission for SEHSCT, BHSCT and NHSCT hospital data, following the introduction of a new electronic healthcare record on 06/11/2023, 06/06/2024 and 07/11/2024 respectively. For this report, all community-acquired admissions for SEHSCT, BHSCT and NHSCT are included, which will include non-emergency admissions (which are a small minority of the total admissions reported). Work is ongoing to adapt systems to new data sources and re-instate differentiation of emergency admissions. Ongoing developmental and quality assurance work may result in adjustments to figures.

7.5.1.1 Influenza and RSV

Community-acquired influenza and RSV emergency admissions to acute hospitals are estimated by combining data from PAS and virological reports in NIHAP. Admissions are counted where there was a positive test up to seven days before admission or up to one day after admission, and the method of admission was ‘Emergency’. The number of inpatients is counted at midnight. Admissions and occupancy refer to the first admission per infection episode.

7.5.1.2 COVID-19

Community-acquired COVID-19 emergency admissions are estimated by combining data from the NI COVID-19 Combined Testing Register and hospital admission information. Admissions are counted where there was a positive PCR or lateral flow test up to 14 days before admission or up to one day after admission. The number of inpatients is counted at midnight. Admissions and occupancy refer to the first admission per infection episode, including transfers between hospitals. The method used in this report is different to that previously reported by the Department of Health’s COVID-19 dashboard, which used administrative coding to identify COVID-19 admissions.

7.6 Mortality surveillance

NISRA death statistics are published weekly, and include weekly counts of deaths related to influenza and/or pneumonia (new from 31 January 2025), and deaths related to COVID-19. This enables comparisons with weekly information published by the Office for National Statistics (ONS) covering England and Wales.

The statistics report on deaths where influenza and/or pneumonia, or COVID-19, was mentioned anywhere on the death certificate. As a result, the counts will reflect deaths where these diseases have contributed to a death but was not necessarily the underlying cause of the death.

8 Supplementary tables

8.1 Unique episodes of influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and week

 

Unique episodes

2025 - 02

Influenza A

393

2025 - 02

Influenza B

84

2025 - 02

RSV

89

2025 - 02

COVID-19

31

2025 - 03

Influenza A

339

2025 - 03

Influenza B

101

2025 - 03

RSV

57

2025 - 03

COVID-19

26

2025 - 04

Influenza A

209

2025 - 04

Influenza B

90

2025 - 04

RSV

56

2025 - 04

COVID-19

27

2025 - 05

Influenza A

111

2025 - 05

Influenza B

99

2025 - 05

RSV

39

2025 - 05

COVID-19

34

2025 - 06

Influenza A

84

2025 - 06

Influenza B

100

2025 - 06

RSV

26

2025 - 06

COVID-19

30

2025 - 07

Influenza A

78

2025 - 07

Influenza B

105

2025 - 07

RSV

18

2025 - 07

COVID-19

28

 

8.2 Influenza, RSV and COVID-19 episode rates per 100,000 population, by age group, over a six week period

 

 

8.3 Influenza, RSV and COVID-19 episode rates per 100,000 population, by local government district, over a six week period

 

 

8.4 Total tests and positivity for influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and Week

 

Total Tests

Total Positives

Positivity (%)

2025 - 02

Influenza

2,470

496

20.08

2025 - 02

RSV

1,455

92

6.32

2025 - 02

COVID-19

2,384

35

1.47

2025 - 03

Influenza

2,260

454

20.09

2025 - 03

RSV

1,322

57

4.31

2025 - 03

COVID-19

2,113

35

1.66

2025 - 04

Influenza

2,139

315

14.73

2025 - 04

RSV

1,207

58

4.81

2025 - 04

COVID-19

2,118

29

1.37

2025 - 05

Influenza

1,959

224

11.43

2025 - 05

RSV

1,136

41

3.61

2025 - 05

COVID-19

1,942

38

1.96

2025 - 06

Influenza

1,775

189

10.65

2025 - 06

RSV

1,065

29

2.72

2025 - 06

COVID-19

1,754

32

1.82

2025 - 07

Influenza

1,659

188

11.33

2025 - 07

RSV

941

18

1.91

2025 - 07

COVID-19

1,642

35

2.13

 

8.5 Total sentinel tests and positivity for influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and Week

 

Total Tests

Total Positives

Positivity (%)

2025 - 02

Influenza

100

46

46.00

2025 - 02

RSV

100

6

6.00

2025 - 02

COVID-19

100

2

2.00

2025 - 03

Influenza

96

35

36.46

2025 - 03

RSV

94

5

5.32

2025 - 03

COVID-19

94

0

0.00

2025 - 04

Influenza

60

20

33.33

2025 - 04

RSV

60

4

6.67

2025 - 04

COVID-19

60

0

0.00

2025 - 05

Influenza

49

12

24.49

2025 - 05

RSV

49

3

6.12

2025 - 05

COVID-19

49

0

0.00

2025 - 06

Influenza

51

14

27.45

2025 - 06

RSV

51

2

3.92

2025 - 06

COVID-19

51

0

0.00

2025 - 07

Influenza

19

5

26.32

2025 - 07

RSV

19

0

0.00

2025 - 07

COVID-19

19

0

0.00

 

8.6 Total non-sentinel tests and positivity for influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and Week

 

Total Tests

Total Positives

Positivity (%)

2025 - 02

Influenza

2,372

450

18.97

2025 - 02

RSV

1,355

86

6.35

2025 - 02

COVID-19

2,286

33

1.44

2025 - 03

Influenza

2,167

421

19.43

2025 - 03

RSV

1,229

52

4.23

2025 - 03

COVID-19

2,021

35

1.73

2025 - 04

Influenza

2,079

295

14.19

2025 - 04

RSV

1,147

54

4.71

2025 - 04

COVID-19

2,058

29

1.41

2025 - 05

Influenza

1,913

213

11.13

2025 - 05

RSV

1,089

39

3.58

2025 - 05

COVID-19

1,896

38

2.00

2025 - 06

Influenza

1,726

176

10.20

2025 - 06

RSV

1,016

28

2.76

2025 - 06

COVID-19

1,705

32

1.88

2025 - 07

Influenza

1,640

183

11.16

2025 - 07

RSV

922

18

1.95

2025 - 07

COVID-19

1,623

35

2.16

 

8.7 Number of sequenced samples for variants in Northern Ireland

Parent Lineage

Cumulative Number Sequenced

BA.2

19

BA.2.86

1

BA.3

30

EG.5.1

1

JN.1

192

KP

74

KP.3

594

Unassigned

261

XBB

1

XEC

140

XEC.2

19

XEC.4

4

XEC.5

3

XEC.8

1

This table only shows counts for lineages with 10 or more sequenced samples from epidemiological year-week 2024 - 07 onwards. Lineage counts include provisional and confirmed sequencing samples. Lineage calls are subject to change following analysis of genomic sequence results, which may result in fluctuations in lineage counts.